Pharmaceuticals
InDex Pharmaceuticals AB is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its TLR platform (toll-like receptors). It discovers and develops DIMS drugs (DNA-based immunomodulatory sequence) to treat diseases within a variety of therapeutic areas, including inflammation and cancer. 

The company has several proprietary DIMS compounds in various stages of development, including Kappaproct^®, for the treatment of steroid resistent/dependent ulcerative colitis, and is entering a clinical Phase III study.

Diagnostics
The company also has a niche strategy in multi-gene diagnostics. Its first diagnostic product DiBiCol^®, which offers a novel standard for gastrointestinal disease classification, is being launched on the Swedish market.

InDex Pharmaceuticals, a spinout from Karolinska Institutet, was founded in 2000 and is based in Stockholm, Sweden. It is a privately owned company with approximately 100 shareholders, including SEB Venture Capital and Life Equity Sweden.